Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program.

ABSTRACT:

Aims/hypothesis

The primary analysis of the Canagliflozin cardioVascular Assessment Study (CANVAS) Program showed canagliflozin to have a beneficial effect on cardiovascular and renal outcomes in people with type 2 diabetes at high cardiovascular risk, but also an unexpected increased risk of major or minor lower extremity amputation. These secondary analyses explore this finding in more detail.

Methods

The effect of canagliflozin on amputation risk in the CANVAS Program was calculated for amputations of different types and proximate aetiologies and different canagliflozin doses. Univariate and multivariate associations of baseline characteristics with amputation risk were determined and proportional and absolute effects of canagliflozin were compared across subgroups.

Re

SUBMITTER: Matthews DR 

PROVIDER: S-EPMC6509073 | biostudies-literature | 2019 Jun

REPOSITORIES: biostudies-literature